News & Updates

Rare and deleterious germline mutations affecting inflammatory response and cellular signaling pathways associate strongly with the time to biochemical recurrence (BCR) after radical treatment in patients with prostate cancer (PrCa), according to a recent study.

Heart diseases, chronic obstructive pulmonary disease (COPD), concomitant cancers, and other co-occurring diseases elevate the risk of death in patients with nonmuscular invasive bladder cancer (NMIBC), nonmetastatic muscle invasive bladder cancer (non-MMIBC), and metastatic bladder cancer (MBC), according to a recent study.

In the phase II NEOBLADE* trial, the addition of the multikinase** inhibitor nintedanib to neoadjuvant chemotherapy (CT) consisting of gemcitabine and cisplatin failed to improve pathological complete response (pCR) and progression-free survival (PFS) in individuals with locally advanced muscle-invasive bladder cancer (MIBC).

The anaplastic lymphoma kinase (ALK) inhibitor ceritinib delivers favourable antitumour activity in ALK-mutated nonsmall cell lung cancer (NSCLC) patients with active brain metastases and/or leptomeningeal disease, according to the phase II ASCEND-7 trial.

Cancer patients who experience treatment delays due to the COVID-19 pandemic restrictions may be vulnerable to psychological distress, reports a recent China study. Effective communication from doctors and other cancer care professionals may help mitigate this effect.

Use of dostarlimab, a single-agent programmed death 1 (PD-1) monoclonal antibody, appears to have successfully cured mismatch repair-deficient, locally advanced rectal cancer, reports a recent study.